Rezvilutamide
Small molecule
Also known as SHR3680
Evidence outlook · registrational
Prostate Cancer: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2027-03.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 2 (1)
What this study did
Appears in other studies (2)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2 (2)
What this study did
What this study did
Competitive landscape
Other Androgen receptor drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Prostate Cancer: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Rezvilutamide: this drug | Phase 3 | Small molecule | Androgen receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Capivasertib | Approved | Small molecule | AKT (inhibitor) | not yet graded | No reviewed efficacy summary in this indication | |
| Docetaxel (Taxotere) | Approved | Small molecule | Microtubules (tubulin) | not yet graded | No reviewed efficacy summary in this indication | |
| Olaparib | Approved | Small molecule | PARP | not yet graded | No reviewed efficacy summary in this indication | |
| Rucaparib | Approved | Small molecule | PARP (poly ADP-ribose polymerase) enzymes, PARP1/2 | Partial signal | No reviewed efficacy summary in this indication | |
| Talazoparib | Approved | Small molecule | PARP | not yet graded | No reviewed efficacy summary in this indication | |
| 225Ac-PSMA-617 | Phase 3 | Radioligand Therapy (actinium-225) | PSMA | not yet graded | No reviewed efficacy summary in this indication | |
| Cabozantinib | Phase 3 | Small molecule | MET / VEGFR / AXL / RET (multi-kinase) | not yet graded | No reviewed efficacy summary in this indication | |
| JNJ-101556143 | Phase 3 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| JNJ-87189401 | Phase 3 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| Rinzimetostat | Phase 3 | Small molecule | EED (PRC2) | not yet graded | No reviewed efficacy summary in this indication | |
| Saruparib | Phase 3 | Small molecule | PARP1 inhibitor (next-gen) | not yet graded | No reviewed efficacy summary in this indication | |
| Abiraterone Decanoate | Phase 2 | Small molecule | CYP17 lyase | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-5041 | Phase 2 | Small molecule | Androgen receptor (degrader) | not yet graded | No reviewed efficacy summary in this indication | |
| Luxdegalutamide | Phase 2(overall) | Small molecule | Androgen receptor, Androgen receptor (degrader) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| MRT-2359 | Phase 2 | Small molecule | GSPT1 | not yet graded | No reviewed efficacy summary in this indication | |
| AMO959 | Phase 1/2 | Small molecule | DNA-PK | not yet graded | No reviewed efficacy summary in this indication | |
| AZD0516 | Phase 1/2 | Antibody–drug conjugate | STEAP2 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD0754 | Phase 1/2 | Cell therapy | STEAP2 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD6621 | Phase 1/2 | Multispecific antibody | STEAP2 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-1738 | Phase 1/2 | Undisclosed | PSMA | not yet graded | No reviewed efficacy summary in this indication | |
| Nezastomig | Phase 1/2 | Multispecific antibody | PSMA x CD28 | not yet graded | No reviewed efficacy summary in this indication | |
| Olsutamig | Phase 1/2 | Multispecific antibody | PSMA x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| REGN15505 | Phase 1/2 | Multispecific antibody | PSMA x 4-1BB | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-4394 | Phase 1/2 | Antibody–drug conjugate | PSMA | not yet graded | No reviewed efficacy summary in this indication | |
| AZD2284 | Phase 1 | Radioconjugate (actinium-225) | STEAP2 | not yet graded | No reviewed efficacy summary in this indication | |
| BMS-986460 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| INR731 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| JANX007 | Phase 1 | Multispecific antibody | PSMA x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| JNJ-95298177 | Phase 1 | Antibody–drug conjugate | — | not yet graded | No reviewed efficacy summary in this indication | |
| JNJ-98768111 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| VIR-5500 | Phase 1 | Multispecific antibody | PSMA x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| GSK5471713 | —(overall) | Undisclosed | Androgen receptor (degrader) | not yet graded | No reviewed efficacy summary in this indication | |
| RG6537 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-7525 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(11 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Rezvilutamide to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.